Biotech · Private company
Silverback Therapeutics
Track this companyFree. Adds Silverback Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- capecitabinePhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- SBT6050Phase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- trastuzumabPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- trastuzumab deruxtecanPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- tucatinibPhase 2 · HER2-positive Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- CemiplimabPhase 1 · HER2 Positive Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- pembrolizumabPhase 1 · HER2 Positive Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- SBT6050Phase 1 · HER2 Positive Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive CancersPHASE1_PHASE2 · TERMINATED · started Feb 8, 2022ClinicalTrials.gov NCT05091528 · fetched Nov 12, 2026
- A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid TumorsPHASE1 · UNKNOWN · started Jul 27, 2020ClinicalTrials.gov NCT04460456 · fetched Nov 12, 2026